Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fisons assaults "undervalued" Rhone-Poulenc Rorer (RPR) bid:

This article was originally published in Clinica

Executive Summary

UK pharmaceutical company Fisons argues in its defence document countering a hostile bid that the Rhone-Poulenc Rorer offer undervalues the sales potential of its asthma medicine delivery devices. RPR's offer stands at 240 pence per share but could be increased by about 20 pence. Fisons' CEO Stuart Wallis says it would require a substantial increase in the offer to tempt Fisons to consider it seriously.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT093195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel